ANIKA THERAPEUTICS Reports Second Quarter Earnings for Fiscal Year 2023

August 17, 2023

🌥️Earnings Overview

On June 30th, 2023, ANIKA THERAPEUTICS ($NASDAQ:ANIK) released their financial results for the second quarter of their 2023 fiscal year. Revenue totaled USD 44.3 million, a 11.7% increase from the same period in the previous year. Net income was -2.7 million, a slight increase from the -2.8 million loss in the same quarter in the preceding year.

Price History

Stock opened at $21.0 and closed at the same price. The company has seen steady growth in recent quarters, due to their innovative range of treatments. Their product portfolio comprises of a range of hyaluronic acid-based products for orthopedic and ophthalmic conditions. These treatments are designed to provide relief from pain and improve the quality of life for various medical conditions. ANIKA THERAPEUTICS‘ products have been approved by the U.S. Food and Drug Administration (FDA) and have received approval from other regulatory bodies around the world. The company also reported an increase in revenue for its second quarter of fiscal year 2023.

This growth was primarily driven by increased sales of their hyaluronic acid-based orthopedic and ophthalmic treatments. The company’s CEO, Andre Nasser, stated that “We are pleased to report another strong quarter of growth for ANIKA THERAPEUTICS. Our innovative products and strong customer base have driven higher revenues which have enabled us to continue our mission of providing relief to those suffering from pain and illness”. The company is looking to continue its strong performance with further product launches and expansions into new markets. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Anika Therapeutics. More…

    Total Revenues Net Income Net Margin
    162.11 -22.17 -13.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Anika Therapeutics. More…

    Operations Investing Financing
    -8.72 -7.07 -10.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Anika Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    328.88 54.87 18.7
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Anika Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    8.9% -12.2% -17.7%
    FCF Margin ROE ROA
    -9.7% -6.5% -5.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of ANIKA THERAPEUTICS‘ wellbeing. Based on our Risk Rating, we would consider ANIKA THERAPEUTICS to be a high risk investment in terms of both financial and business aspects. We detected two risk warnings within ANIKA THERAPEUTICS’ income sheet and balance sheet, which could indicate future forecast issues. If you would like to learn more about our analysis and findings, please register on for further details. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The medical device industry is competitive, with companies vying for market share in a number of different therapeutic areas. Anika Therapeutics Inc is one such company, competing against Neovasc Inc, NovoCure Ltd, and REMSleep Holdings Inc in the area of tissue repair and regeneration. While each company has its own unique products and approaches, they all share the goal of helping patients heal from injuries and improve their quality of life.

    – Neovasc Inc ($TSX:NVCN)

    Neovasc Inc is a specialty medical device company that develops, manufactures and markets products for cardiovascular diseases. The Company’s products include the Tiara technology for transcatheter mitral valve replacement, the Neovasc Reducer for the treatment of refractory angina, and the Peripatch tissue patch.

    Neovasc’s market cap is 24.41M as of 2022. The company has a return on equity of -49.9%. Neovasc’s products include the Tiara technology for transcatheter mitral valve replacement, the Neovasc Reducer for the treatment of refractory angina, and the Peripatch tissue patch.

    – NovoCure Ltd ($NASDAQ:NVCR)

    NovoCure Ltd is a commercial-stage oncology company developing a novel therapy called TTFields for the treatment of solid tumor cancers. The company’s therapy is based on the use of low-intensity, alternating electric fields, which have been shown to disrupt cancer cell division, leading to cell death. NovoCure’s therapy is currently approved for the treatment of glioblastoma, a type of brain cancer, in the United States, Europe, and Israel. The company is also evaluating its therapy in clinical trials for other types of solid tumor cancers, including ovarian cancer, pancreatic cancer, and non-small cell lung cancer.

    NovoCure’s market cap as of 2022 is 8.04B. The company’s return on equity (ROE) is -8.29%.

    NovoCure’s market cap is large relative to its ROE because its ROE is negative. This means that the company is not generating a profit from its operations. The company’s market cap is also large relative to its revenue, which was $204.5 million in 2020. This is because investors are hopeful that NovoCure’s therapy will be approved for additional indications and that the company will become profitable in the future.

    – REMSleep Holdings Inc ($OTCPK:RMSL)

    REM Sleep Holdings Inc is a publicly traded company with a market cap of 20.75M as of 2022. The company has a Return on Equity of -17.66%. REM Sleep Holdings Inc is a diversified holding company with interests in a variety of businesses, including but not limited to: healthcare, technology, media, and consumer products.


    ANIKA THERAPEUTICS reported their earnings for the second quarter of their fiscal year 2023 and saw an 11.7% increase in total revenue, bringing it to 44.3 million USD. Net income was -2.7 million USD, a slight improvement from the -2.8 million USD loss in the same quarter last year. Investors should consider this company as they have seen a steady increase in revenue and have experienced a slight improvement in net income. ANIKA THERAPEUTICS has potential for growth and could be a good investing opportunity for those looking for a long-term strategy.

    Recent Posts

    Leave a Comment